Short answer: For most women without a personal history of breast cancer, modern HRT carries a small change in breast cancer risk that’s genuinely comparable to, or smaller than, everyday risk factors like carrying extra weight after menopause or drinking a couple of glasses of wine most nights. It’s not a simple yes or no, and once you see it alongside the real benefits for bone and heart health, the picture looks very different to the one most women have in their head.
This is the question underneath almost every other question I get asked about HRT. Women will sit across from me ready to talk about hot flashes and sleep, and what they actually want to know, often without saying it outright, is whether taking hormones is going to give them cancer. So let’s talk about it directly, with the full picture, not just the frightening headline.
Why the Fear Runs So Deep
Survey data confirms what I see constantly in clinic: a substantial proportion of postmenopausal women believe HRT increases breast cancer risk, and a large proportion more simply aren’t sure. That uncertainty is doing real harm. Women are avoiding a treatment that could meaningfully improve their quality of life, based on information that’s twenty years out of date and rarely presented alongside any real context.
Where the Fear Came From
Most of it traces back to the Women’s Health Initiative (WHI) study, published in the early 2000s, which reported increased risks of breast cancer, heart disease, and stroke with certain HRT formulations. What the popular retelling usually leaves out:
- The study largely used older-style oral hormones and a synthetic progestin, not the body-identical, transdermal options commonly used today
- The average participant was significantly older than most women are now when they start HRT
- Later re-analyses have refined the risk picture considerably, particularly for women who start therapy closer to the menopause transition rather than years afterward
How This Risk Actually Compares to Everyday Choices
Here’s the context almost nobody gives you. According to the British Menopause Society’s Women’s Health Concern, the increase in breast cancer risk from combined HRT is smaller than the increase linked to being overweight after age 50, and smaller than the increase linked to drinking two or more standard drinks of alcohol a day. Oestrogen-only HRT, used by women who’ve had a hysterectomy, is associated with little to no change in breast cancer risk at all. Put together, current or past HRT use is thought to account for around 2% of breast cancer cases in the UK.
None of this means HRT carries zero consideration, and it doesn’t mean lifestyle factors should be ignored either. But it does mean the fear attached to HRT is wildly out of proportion to the fear attached to a glass of wine most nights, which most women don’t think twice about. Context matters, and this is context that rarely makes it into the conversation.
Two Details Often Left Out, Both in HRT’s Favour
There are two facts that rarely make it into the popular version of this story, and both push in a more reassuring direction than most women expect.
First, the WHI study wasn’t one trial, it was two. Women with a uterus were given combined oestrogen and progestogen, and that arm showed an increased breast cancer risk. But women who’d already had a hysterectomy were given oestrogen alone, with no progestogen, and that arm told a different story entirely. In the final 2006 report, women on oestrogen-only therapy had a statistically significant 20% lower risk of invasive breast cancer than women on placebo. This distinction between the two hormone types gets lost almost every time this topic comes up casually, and it matters.
Second, when HRT prescribing collapsed after the 2002 WHI publication, some researchers pointed to a subsequent fall in breast cancer incidence rates as proof that HRT was driving the risk. That claim is genuinely contested, not settled. Critics of this interpretation, including Dr Avrum Bluming and Carol Tavris in Estrogen Matters, point out that the decline in breast cancer incidence actually began around 1999, roughly three years before HRT use fell sharply, which is difficult to explain if HRT withdrawal were the cause. At least one large study looking at English prescribing and cancer data over the same period found no statistical relationship between the fall in HRT use and breast cancer trends at all. This remains an active, unresolved scientific debate, and it’s worth knowing the story is far less clear-cut than the headlines from 2002 suggested.
The Benefits Worth Weighing Just as Seriously
Risk conversations about HRT rarely get matched with an equally clear-eyed look at the benefits, and that’s a genuine gap. The data here is solid:
- Bone health. HRT reduces the risk of hip fracture by around 33%, equivalent to roughly 6 fewer hip fractures per 10,000 women treated per year. This effect has been shown consistently across both combined and oestrogen-only formulations.
- Heart health. For women who start HRT within 10 years of menopause or before age 60, a meta-analysis of 19 trials found significantly lower all-cause mortality and around half the risk of coronary heart disease compared with women not on HRT. This is often called the “timing hypothesis,” and it’s a major reason why starting HRT earlier in the menopause transition matters clinically, not just for symptom relief.
- Quality of life. Beyond the statistics, effective treatment of hot flashes, sleep disruption, mood symptoms, and vaginal and urinary symptoms has a real, cumulative impact on day-to-day wellbeing that doesn’t always show up in a risk-benefit table but matters enormously in practice.
Putting an Actual Number on the Breast Cancer Risk
Based on UK population data, roughly 63 in every 1000 women aged 50 to 69 who never use HRT will be diagnosed with breast cancer over that twenty-year span. With five years of oestrogen-only HRT, that figure rises by around 5 extra cases per 1000 women, a difference that isn’t statistically significant. With five years of combined oestrogen and progestogen HRT, it rises by around 14 extra cases per 1000 women. These are population averages, not a prediction for any individual, and they shift depending on your age, the specific hormone type, and how long you use it.
What This Looks Like in a Real Consultation
There is no single universal answer here, which is exactly why it needs to be worked through with you, weighing the real risks against the real benefits, not settled by a headline or your sister’s experience. A proper conversation covers:
- Your personal and family cancer history
- The specific symptoms you’re hoping to address
- The type, dose, and delivery method of hormone therapy being considered
- Your cardiovascular and bone health risk profile
- What screening and monitoring looks like going forward
Frequently Asked Questions
Is bioidentical HRT safer than older forms?
Body-identical hormone therapy, delivered transdermally, is generally considered to carry a more favourable risk profile than some older oral formulations, though “safer” still depends on your individual context.
How does HRT’s breast cancer risk compare to other things I might not think twice about?
The risk increase from combined HRT is generally smaller than that linked to being overweight after age 50, or to drinking two or more standard alcoholic drinks a day.
Can I use HRT if my mother or sister had breast cancer?
Family history doesn’t automatically exclude HRT, though it’s an important factor in the discussion and may affect screening.
Does stopping HRT lower my risk again?
Risk profiles can shift after stopping. This is worth discussing with your doctor in the context of your individual history.
Is vaginal (local) oestrogen the same risk as systemic HRT?
No. Local vaginal oestrogen generally carries a different, more favourable risk profile, since very little reaches the bloodstream.
What are the actual benefits of HRT beyond symptom relief?
Around a 33% reduction in hip fracture risk, and for women who start within 10 years of menopause or before 60, meaningfully lower rates of coronary heart disease and all-cause mortality.
Further Reading and Support
- Menopause and Cancer, founded by Dani Binnington, is a dedicated, expert-led resource for anyone navigating menopause during or after a cancer diagnosis, including specific guidance on symptom management when HRT isn’t an option.
- Estrogen Matters by oncologist Dr Avrum Bluming and social psychologist Carol Tavris walks through the history of the Women’s Health Initiative study and the research that has followed, written specifically to unpack the fear this article addresses.
- Your own GP or specialist remains the best source for how any of this applies to your specific history. General reading is useful context, not a substitute for that conversation.
This deserves an unhurried conversation, weighing the whole picture, not a five-minute scroll through worst-case stories. Bring your history and your questions in, and let’s actually work through it.
| WHERE TO START: Hormone Replacement Therapy (HRT) – what the treatment involves, the delivery methods available, and how it is assessed against your history. Menopause Consultation – the unhurried conversation this topic actually deserves. Both available at Forresters Beach and The Junction. No GP referral needed. |
This article is general information and doesn’t replace individualised medical advice.